Unlike CD19 or BCMA in lymphoma/leukemia, which are uniformly expressed on tumor cells and are only coexpressed by dispensable cell types, such as normal B cells, the expression of potential CAR target antigens in solid tumors is more heterogeneous and frequently not restricted to tumor cells or dispensable cell types [14]. This evidence concerns the gene CD19 and neoplasm.